Cushing’s syndrome, characterized by prolonged exposure to elevated levels of cortisol, presents a complex diagnostic challenge. While often iatrogenic due to corticosteroid use, endogenous Cushing’s syndrome requires careful differentiation from other conditions that mimic its signs and symptoms. This article provides an in-depth look at the differential diagnosis of Cushing’s syndrome, crucial for accurate diagnosis and effective management.
Understanding Cushing’s Syndrome and Its Mimics
Cushing’s syndrome, also known as hypercortisolism, arises from excessive cortisol in the body. While exogenous steroid administration is the most prevalent cause, endogenous Cushing’s can stem from ACTH-dependent sources like pituitary adenomas (Cushing’s disease) or ectopic ACTH secretion, and ACTH-independent causes such as adrenal tumors. The clinical features of Cushing’s syndrome are varied, including weight gain, characteristic fat distribution (buffalo hump, moon face), skin changes (striae, easy bruising), muscle weakness, and metabolic disturbances. However, many of these symptoms are non-specific and can overlap with other common conditions, necessitating a robust differential diagnostic approach.
Conditions Mimicking Cushing’s Syndrome
Several conditions can present with features similar to Cushing’s syndrome, leading to potential diagnostic confusion. These “pseudo-Cushing’s states” often share clinical overlap but have distinct underlying mechanisms and require different management strategies. Key conditions in the differential diagnosis include:
1. Obesity
Obesity, particularly with central fat distribution, can mimic the appearance of Cushing’s syndrome. Patients may exhibit increased abdominal fat, facial rounding, and even striae. However, in obesity, these striae are typically white or pale, unlike the characteristic purplish striae of Cushing’s. Furthermore, metabolic abnormalities such as insulin resistance and hypertension are common in both conditions. Crucially, individuals with simple obesity will demonstrate normal cortisol levels and normal results on dexamethasone suppression tests, distinguishing it from true Cushing’s syndrome.
2. Polycystic Ovary Syndrome (PCOS)
PCOS, a common endocrine disorder in women, can share several features with Cushing’s syndrome, including weight gain, menstrual irregularities, hirsutism, and acne. Insulin resistance and metabolic syndrome are also frequently observed in PCOS. While hyperandrogenism is the hallmark of PCOS, some features may superficially resemble hypercortisolism. However, hormonal evaluation will reveal elevated androgens in PCOS, while Cushing’s syndrome is defined by hypercortisolism. Dexamethasone suppression tests will be normal in PCOS.
3. Depression and Psychiatric Disorders
Certain psychiatric conditions, particularly depression, anxiety disorders, and obsessive-compulsive disorder, can be associated with hypothalamic-pituitary-adrenal (HPA) axis activation, leading to mild hypercortisolism. This “pseudo-Cushing’s” of depression can result in fatigue, sleep disturbances, and appetite changes, symptoms that can overlap with Cushing’s syndrome. However, the degree of hypercortisolism in these psychiatric conditions is usually less pronounced than in Cushing’s syndrome. Furthermore, dexamethasone suppression tests may show incomplete suppression, but cortisol levels are typically not as markedly elevated as in true Cushing’s. Clinical context and psychiatric evaluation are essential in differentiating these conditions.
4. Alcohol Use Disorder
Chronic excessive alcohol consumption can induce a pseudo-Cushing’s state. Alcohol directly affects the HPA axis, leading to increased cortisol secretion. Individuals with alcohol use disorder may present with Cushingoid features such as facial plethora, weight gain, and hypertension. Biochemical testing may reveal elevated cortisol levels and abnormal dexamethasone suppression tests. However, these abnormalities typically resolve with alcohol abstinence, distinguishing it from Cushing’s syndrome. A thorough history of alcohol intake is critical in the differential diagnosis.
5. Uncontrolled Diabetes Mellitus
Poorly controlled diabetes mellitus, especially type 2 diabetes, can manifest with symptoms that overlap with Cushing’s syndrome. Insulin resistance, weight gain, fatigue, and skin changes can be seen in both conditions. Hyperglycemia and its associated complications are prominent in diabetes but are secondary findings in Cushing’s syndrome. While Cushing’s syndrome can induce diabetes, poorly controlled diabetes alone does not cause the characteristic hormonal abnormalities of Cushing’s. Blood glucose levels and HbA1c are key differentiating factors, along with cortisol-specific testing.
6. Bulimia Nervosa
Bulimia nervosa, an eating disorder characterized by binge eating and compensatory behaviors, can also lead to HPA axis dysregulation and pseudo-Cushing’s. The stress associated with the disorder and the metabolic consequences of purging can elevate cortisol levels. Patients may exhibit some Cushingoid features, but these are typically less pronounced and resolve with the management of the eating disorder. Psychiatric evaluation and focus on eating behaviors are crucial for diagnosis.
Diagnostic Tools for Differential Diagnosis
Differentiating Cushing’s syndrome from its mimics requires a systematic diagnostic approach, combining clinical assessment with specific laboratory and imaging tests.
1. Initial Screening Tests for Hypercortisolism
- Late-Night Salivary Cortisol: This test measures cortisol levels in saliva collected late at night, when cortisol should be at its lowest. Elevated levels suggest hypercortisolism. However, false positives can occur due to factors like smoking or licorice consumption.
- 24-Hour Urinary Free Cortisol (UFC): This test measures the total amount of cortisol excreted in the urine over a 24-hour period. Elevated UFC levels are indicative of hypercortisolism. Accurate collection is crucial, and kidney function needs to be considered as low GFR can affect results.
- Overnight Dexamethasone Suppression Test (ONDST): This test assesses the suppressibility of cortisol production by dexamethasone, a synthetic glucocorticoid. Failure to suppress cortisol levels after dexamethasone administration suggests Cushing’s syndrome.
2. Confirmatory and Differential Diagnostic Tests
- Low-Dose Dexamethasone Suppression Test (LDDST): This more prolonged dexamethasone suppression test helps to confirm hypercortisolism and differentiate Cushing’s syndrome from pseudo-Cushing’s states. In pseudo-Cushing’s, cortisol suppression may be incomplete but is generally greater than in true Cushing’s.
- Serum ACTH Levels: Measuring ACTH levels helps differentiate between ACTH-dependent and ACTH-independent Cushing’s syndrome. Elevated or inappropriately normal ACTH levels suggest ACTH-dependent causes (Cushing’s disease or ectopic ACTH), while low ACTH levels point towards ACTH-independent causes (adrenal tumors).
- High-Dose Dexamethasone Suppression Test (HDDST): In ACTH-dependent Cushing’s syndrome, HDDST can help differentiate between pituitary Cushing’s disease and ectopic ACTH secretion. Suppression of cortisol with high-dose dexamethasone suggests pituitary Cushing’s disease, while lack of suppression indicates ectopic ACTH production.
- Corticotropin-Releasing Hormone (CRH) Stimulation Test: This test can further differentiate pituitary Cushing’s disease from ectopic ACTH secretion. Patients with pituitary Cushing’s disease typically show an increase in ACTH and cortisol levels after CRH stimulation, whereas those with ectopic ACTH syndrome usually do not.
- Inferior Petrosal Sinus Sampling (IPSS): IPSS is an invasive procedure used to differentiate pituitary from ectopic ACTH secretion when other tests are inconclusive. ACTH levels are measured in blood samples taken from the inferior petrosal sinuses (draining the pituitary gland) and peripheral blood. A central-to-peripheral ACTH ratio greater than 2:1 (or >3:1 after CRH stimulation) confirms pituitary Cushing’s disease.
- Imaging Studies: Pituitary MRI is used to detect pituitary adenomas in Cushing’s disease. CT scans of the adrenal glands are used to identify adrenal adenomas or carcinomas. Chest and abdominal CT scans may be necessary to locate ectopic ACTH-secreting tumors.
Importance of Accurate Differential Diagnosis
Accurate differential diagnosis of Cushing’s syndrome is paramount for appropriate management and preventing long-term complications. Misdiagnosis can lead to unnecessary treatments, delayed management of the underlying condition, and increased patient morbidity. Distinguishing Cushing’s syndrome from its mimics ensures that patients receive the correct interventions, whether it’s surgical resection of a tumor, medication to manage cortisol levels, or addressing underlying lifestyle factors or psychiatric conditions.
Conclusion
The differential diagnosis of Cushing’s syndrome is a nuanced process requiring careful clinical evaluation and judicious use of diagnostic testing. Understanding the conditions that mimic Cushing’s syndrome, employing appropriate screening and confirmatory tests, and integrating clinical context are crucial steps in achieving diagnostic accuracy. By systematically considering the differential diagnosis, healthcare professionals can ensure timely and effective management, improving outcomes for patients with true Cushing’s syndrome and avoiding unnecessary interventions for those with mimicking conditions.
Figure: Vertical purplish abdominal striae are a characteristic skin finding in Cushing’s syndrome, aiding in differential diagnosis from conditions with similar symptoms but different skin manifestations.
References
1.Hirsch D, Shimon I, Manisterski Y, Aviran-Barak N, Amitai O, Nadler V, Alboim S, Kopel V, Tsvetov G. Cushing’s syndrome: comparison between Cushing’s disease and adrenal Cushing’s. Endocrine. 2018 Dec;62(3):712-720. [PubMed: 30084101]
2.Lodish MB, Keil MF, Stratakis CA. Cushing’s Syndrome in Pediatrics: An Update. Endocrinol Metab Clin North Am. 2018 Jun;47(2):451-462. [PMC free article: PMC5962291] [PubMed: 29754644]
3.Nieman LK. Recent Updates on the Diagnosis and Management of Cushing’s Syndrome. Endocrinol Metab (Seoul). 2018 Jun;33(2):139-146. [PMC free article: PMC6021313] [PubMed: 29947171]
4.Osswald A, Deutschbein T, Berr CM, Plomer E, Mickisch A, Ritzel K, Schopohl J, Beuschlein F, Fassnacht M, Hahner S, Reincke M. Surviving ectopic Cushing’s syndrome: quality of life, cardiovascular and metabolic outcomes in comparison to Cushing’s disease during long-term follow-up. Eur J Endocrinol. 2018 Aug;179(2):109-116. [PubMed: 29875286]
5.Zhao Y, Guo H, Zhao Y, Shi B. Secreting ectopic adrenal adenoma: A rare condition to be aware of. Ann Endocrinol (Paris). 2018 Apr;79(2):75-81. [PubMed: 29525561]
6.O’Brien KF, DeKlotz CMC, Silverman RA. Exogenous Cushing syndrome from an unexpected source of systemic steroids. Pediatr Dermatol. 2018 May;35(3):e196-e197. [PubMed: 29574945]
7.Tatsi C, Keil M, Lyssikatos C, Belyavskaya E, Stratakis CA, Lodish MB. Incidence of Autoimmune and Related Disorders After Resolution of Endogenous Cushing Syndrome in Children. Horm Metab Res. 2018 Apr;50(4):290-295. [PMC free article: PMC6341463] [PubMed: 29458220]
8.Yang J, Shen J, Fuller PJ. Diagnosing endocrine hypertension: a practical approach. Nephrology (Carlton). 2017 Sep;22(9):663-677. [PubMed: 28556585]
9.Moreira AC, Antonini SR, de Castro M. MECHANISMS IN ENDOCRINOLOGY: A sense of time of the glucocorticoid circadian clock: from the ontogeny to the diagnosis of Cushing’s syndrome. Eur J Endocrinol. 2018 Jul;179(1):R1-R18. [PubMed: 29661784]
10.Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008 May;93(5):1526-40. [PMC free article: PMC2386281] [PubMed: 18334580]
11.Laudat MH, Cerdas S, Fournier C, Guiban D, Guilhaume B, Luton JP. Salivary cortisol measurement: a practical approach to assess pituitary-adrenal function. J Clin Endocrinol Metab. 1988 Feb;66(2):343-8. [PubMed: 2828410]
12.Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A., Endocrine Society. Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015 Aug;100(8):2807-31. [PMC free article: PMC4525003] [PubMed: 26222757]
13.Bertagna X. MANAGEMENT OF ENDOCRINE DISEASE: Can we cure Cushing’s disease? A personal view. Eur J Endocrinol. 2018 May;178(5):R183-R200. [PubMed: 29467229]
14.Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Gastrointestinal and endocrinologic side effects. J Am Acad Dermatol. 2017 Jan;76(1):11-16. [PubMed: 27986133]
15.Warriner AH, Saag KG. Glucocorticoid-related bone changes from endogenous or exogenous glucocorticoids. Curr Opin Endocrinol Diabetes Obes. 2013 Dec;20(6):510-6. [PubMed: 24468753]
16.Caimari F, Valassi E, Garbayo P, Steffensen C, Santos A, Corcoy R, Webb SM. Cushing’s syndrome and pregnancy outcomes: a systematic review of published cases. Endocrine. 2017 Feb;55(2):555-563. [PubMed: 27704478]
